68Ga-FAPI PET-CT to image inflammation in Sjögren's syndrome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective interventional imaging study using 68Ga-FAPI PET-CT to characterize uptake patterns in patients with primary Sjögren's syndrome and a control group of patients with solid tumors. Adults aged 18–80 who meet the 2016 ACR-EULAR criteria for primary Sjögren's or tumor patients scheduled for FAPI imaging will undergo PET-CT and quantitative analysis of glandular and extra-glandular uptake. Patients with other connective tissue diseases, concurrent tumors in the Sjögren's group, current hormone or biological therapy, or who are pregnant or breastfeeding will be excluded. Imaging findings will be compared between the groups to determine whether FAPI uptake correlates with inflammatory activity in Sjögren's syndrome and could help guide clinical management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18-80 years;
* Fulfillment of the 2016 ACR-EULAR Classification Criteria for pSS at enrollment. OR diagnosis of a solid tumor scheduled for FAPI PET imaging

Exclusion Criteria:

* Combined with tumors or other connective tissue diseases (for SS group);
* Patients who are currently using hormones/biological agents (for both groups)；
* Pregnancy or lactation

Where it's running

• Peking Union Medical College Hospital
  Beijing, China Recruiting

Study contacts

• Study coordinator: Zhaohui Zhu, MD
• Email: 13611093752@163.com
• Phone: 13611093752

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pain patterns in rheumatic diseases: see if pain works differently in patients and healthy people

  This observational study tests how pain is experienced and measured in people with rheumatic diseases compared with healthy volunteers.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07829497

• First-in-human test of CND319 in healthy people and people with rheumatic diseases

  This early study tests whether CND319 is safe and tolerable and whether it shows any signs of activity in healthy adults and in people with rheumatoid arthritis or Sjogren's syndrome.

  Recruiting Phase 1 Candid Therapeutics · Melbourne, Victoria · NCT07712939

• Tofacitinib safety for people with primary Sjogren disease

  This study will test whether the oral pill tofacitinib is safe and tolerable for adults with primary Sjogren disease and mild-to-moderate symptoms.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07281456

• YTS109 cell therapy for relapsed or refractory autoimmune diseases

  This will try a single infusion of YTS109 immune cells to see if they are safe and help adults 18–65 with relapsed or refractory lupus (including lupus nephritis), Sjogren's syndrome, inflammatory myopathy, or ANCA‑associated vasculitis.

  Recruiting Phase 1 China Immunotech (Beijing) Biotechnology Co., Ltd. · Bengbu · NCT07236762

• Creating Health online course for people with rheumatological conditions

  This project will test whether an online course about diet and self-care helps adults with rheumatoid arthritis, Sjogren's syndrome, lupus, mixed connective tissue disease, or psoriatic arthritis reduce fatigue and improve quality of life.

  Recruiting University of Iowa · Iowa City, Iowa · NCT07180537

• CLN-978 injections for people with moderate to severe Sjögren's disease

  This trial will try subcutaneous injections of CLN-978, a CD19-directed T cell engager, in adults with active moderate-to-severe Sjögren's disease to see if it reduces disease activity.

  Recruiting at 14 sites Phase 1 Cullinan Therapeutics Inc. · Orlando, Florida and 13 other locations · NCT07041099

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.